Forte Biosciences director granted 18,353 RSUs

Brun Scott C. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Brun Scott C. reported acquisition or exercise transactions in this Form 4 filing.

Forte Biosciences, Inc. director Scott C. Brun reported receiving a grant of 18,353 restricted stock units (RSUs) tied to the company’s common stock. Each RSU represents a contingent right to receive one share of Forte common stock.

The award vests in full at the first annual stockholder meeting that occurs after May 29, 2026, as long as Brun continues serving as a “Service Provider” under the company’s 2021 Equity Incentive Plan through that date. Following this grant, he holds 18,353 RSUs directly, reflecting equity-based compensation rather than an open‑market purchase or sale.

Insider Trade Summary

Grant/Award: 18,353 shares

Grant/Award 1 txn

Insider Brun Scott C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	18,353	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 18,353 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
2. F2. Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026.

Key Figures

RSUs granted: 18,353 units Underlying common shares: 18,353 shares Post‑grant RSU holdings: 18,353 units

3 metrics

RSUs granted 18,353 units Restricted stock units awarded on May 29, 2026

Underlying common shares 18,353 shares Each RSU equals one share of common stock

Post‑grant RSU holdings 18,353 units Total RSUs held following this transaction

Key Terms

Restricted Stock Units, 2021 Equity Incentive Plan, Service Provider, Grant, award, or other acquisition

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2021 Equity Incentive Plan financial

"Service Provider (as defined in the 2021 Equity Incentive Plan) through such date"

Service Provider financial

"Subject to the Reporting Person's continuing as a Service Provider"

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Forte Biosciences (FBRX) director Scott C. Brun report on this Form 4?

Scott C. Brun reported receiving a grant of 18,353 restricted stock units (RSUs) tied to Forte Biosciences common stock. This is an equity compensation award, not an open-market stock purchase or sale, and is recorded as a derivative transaction on the Form 4.

How many Forte Biosciences (FBRX) RSUs did Scott C. Brun receive?

Scott C. Brun received 18,353 restricted stock units. Each RSU represents a contingent right to receive one share of Forte Biosciences common stock, giving him potential future ownership if vesting conditions specified in the award are satisfied.

When do Scott C. Brun’s Forte Biosciences (FBRX) RSUs vest?

All 18,353 RSUs vest on the date of the first annual meeting of stockholders occurring after May 29, 2026. Vesting is conditioned on Brun continuing as a Service Provider, as defined under Forte Biosciences’ 2021 Equity Incentive Plan, through that meeting date.

Is Scott C. Brun’s Form 4 for Forte Biosciences (FBRX) a stock purchase or sale?

The Form 4 reflects an award of restricted stock units, not a stock purchase or sale. The transaction code is “A,” indicating a grant or award acquisition of 18,353 RSUs as compensation, with no open-market trading activity reported in this filing.

What does each Forte Biosciences (FBRX) restricted stock unit represent in this filing?

Each restricted stock unit represents a contingent right to receive one share of Forte Biosciences common stock. The units convert into shares only if the vesting condition—continued service through the specified post–May 29, 2026 annual stockholder meeting—is satisfied by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:36 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brun Scott C.

(Last) (First) (Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BUILDING 6

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/29/2026		A		18,353		(2)	(2)	Common Stock	18,353	$0	18,353	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

2. Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026.

	/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)